Heart gene therapy maker Tenaya Therapeutics is laying off 30% to 40% of its staff by the end of the year, the company’s CEO Faraz Ali told Endpoints News by email.
Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad cholesterol ...
The FDA has permitted eGenesis to begin a clinical trial of a dialysis-like system that involves using a gene-edited pig liver outside of the body. It’s the second formal study ...
Roche is stopping patients on the low dose of its experimental Huntington’s drug tominersen, and will be transitioning them to the high dose following recommendations by an independent data monitoring committee.
Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in a key study of an aggressive form of breast cancer.
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year.
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA decision expected by June 23
Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in lymphoma and myeloma patients without lymphodepletion.
Rocket Pharmaceuticals reports early success in gene therapy trial for heart condition PKP2-ACM, with 3 patients showing improved heart function. One had severe side effects.
Sarepta Therapeutics is meeting with the FDA in June to discuss expanding the use of its Duchenne muscular dystrophy gene therapy to patients younger than 4 years old.
